An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

Conditions

• Hyperkalaemia

Interventions

• DRUG: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level
• DRUG: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)
• DRUG: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)
• DRUG: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)
• DRUG: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase

Sponsor

AstraZeneca